PRAME and breast carcinoma: To date, numerous ongoing clinical trials are studying the safety and efficacy of targeting PRAME using ex vivo expanded multi-TAA-specific T cells in hematological malignancies (NCT02291848, NCT02475707, NCT02494167 and NCT02203903), neuro-oncologic disease (NCT03652545), rhabdomyosarcoma (NCT02239861), pancreatic cancer (NCT03192462), breast cancer (NCT03093350), and a range of high-risk solid tumors (NCT02789228).